Patients with cholangiocarcinoma and disease progression after at least one previous treatment were assigned to one of three cohorts: patients with FGFR2-fusions or rearrangements, patients with other FGFR alterations, or patients with no FGFR alterations. This evidence concerns the gene FGFR2 and cholangiocarcinoma.